Home > Oncology > ELCC 2019 > Immunotherapy in Stage 4 Lung Cancer > Combo I-O plus chemotherapy

Combo I-O plus chemotherapy

Presented By
Dr Luis Paz-Ares, Complutense University of Madrid, Spain
Conference
ELCC 2019
Trial
Keynote-189, Impower-132
Chemotherapy has historically been considered immune-suppressive. The recent success of immune checkpoint inhibitors (ICI) has renewed interest in immunotherapies, and in combining them with chemotherapy to achieve additive or synergistic clinical activity [1,2]. Dr Luis Paz-Ares (Complutense University of Madrid, Spain) gave an overview about the combination of I-O and chemotherapy. The data of previous phase 1 studies evaluating front-line therapy of anti-PD-L1 or anti-PD1 agents in combination with chemotherapy were “not overwhelming”, Dr Paz-Ares mentioned [3]. “The response rates were in the range of 50%.” However, further research showed some more positive results. For example, the open-label Keynote-021 suggests that combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC [4]. Subsequently, the Keynote-189 trial showed that in patie...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on